Labiotech.eu

In Depth 23 Nov 2017

The Future is (Syn)Bio: How and when do we get there?

Last week, Philip and I attended a meeting with some of the pioneers and leaders of the synthetic biology field. They believe biology will be everywhere in the future, but how do we get ready for it? Digital technologies are now present in almost all aspects of our lives. It seems obvious today that companies […]

November 23, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Nov 2017

Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout

Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a Phase I trial. Galapagos is a clinical-stage biotech developing small molecule medicines for a range of indications. It partnered up with the global pharma company, AbbVie, back in 2013, to develop a number of cystic fibrosis (CF) candidates for a […]

November 22, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Welsh Scientists Use CRISPR to Engineer Cancer-Killing T cells

Scientists at Cardiff University have used CRISPR/Cas9 genome editing technology to produce highly specific killer T cell receptors. Researchers at Cardiff University have replaced the regular receptors found on T cells with their own, which are geared up to better tracking down and killing cancer cells. The research reported in Blood explained how the group removed receptors that interact with immune cells […]

November 22, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

Alzheimer’s disease is rapidly increasing in prevalence but we have no effective treatment. But, Finnish Researchers have found a new target to investigate. Researchers at the University of East Finland have found that astrocytes, the cells that support the brain, could play a major role in the pathogenesis of Alzheimer’s disease. The research, published in […]

November 22, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Streamlining Vaccine R&D with Labflow Automation

In recent years, awareness for the automation of laboratory workflows has increased dramatically. As a result, researchers have worked tirelessly to make the improvement of lab digitalization and sensor technologies a main priority. Being able to collect large quantities of data from R&D and Quality Control (QC) in a short amount of time, has the […]

November 22, 2017 - 5 minutesmins - By External Contributor

Infographics 22 Nov 2017

Infographic: What is RNAi Therapy? Targeting the Untargetable

Everything you need to know about what RNAi is, how it works and how it could soon change the way we treat all sorts of diseases. A new wave of therapies based on RNA interference is on the brink of making it to the market. A technology that was awarded the Nobel prize in 2006, […]

November 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Nov 2017

Can this French Biotech Make it Easier to Rescue People from Hypoglycemia?

Adocia’s ready-to-use glucagon has proved to be safe in phase I trials. The company believes it can overthrow Novo Nordisk and Eli Lilly in rescuing severe hypoglycemia. Based in Lyon, France, Adocia develops new formulations to improve the performance of diabetes drugs, including an ultra-rapid insulin to help type 1 diabetics control their blood glucose levels […]

November 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Nov 2017

German Biotech Reels in €34M for its Cancer-Killing Technology

Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development of its Antibody Targeted Amanitin Conjugates (ATACs) technology. The biotech, formerly Wilex, is developing drugs for cancer and autoimmune diseases, with the hope that the addition of Amanitin to antibody-drug conjugate (ADC) technology could produce […]

November 21, 2017 - 1 minutemin - By Alex Dale

News and Trends 21 Nov 2017

French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A

Step Pharma will use the proceeds of its first fundraising round to support the development of immunomodulators for autoimmune diseases towards the clinic. Step Pharma develops inhibitors targeting an enzyme called cytidine nucleotide triphosphate (CTPS1) for the treatment of a range of autoimmune diseases. The company is working on several candidates, the most advanced of which […]

November 21, 2017 - 3 minutesmins - By Alex Dale

News and Trends 21 Nov 2017

Welcome to Amsterdam, EMA! Your New Home Post-Brexit

Last year’s Brexit vote left the European Medicines Agency (EMA) searching for a new home. Last night, it was revealed that it will relocate to Amsterdam. Yesterday, representatives from each of the member states voted for the new location of the European Medicines Agency (EMA). In the end, it came down to a coin toss that […]

November 21, 2017 - 3 minutesmins - By Alex Dale

News and Trends 20 Nov 2017

British and German Scientists Chuck Proteins in the Trash to Uncover their Function

Trim-Away removes a protein to uncover its true function, which will support disease research and potentially the development of new therapies. Scientists at the Medical Research Council in the UK and the Max Planck Institute in Germany have discovered Trim-Away, a new technique that can remove a protein from a cell so that its true function can […]

November 20, 2017 - 3 minutesmins - By Alex Dale

News and Trends 20 Nov 2017

After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy

DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45% last month after releasing Phase III data for ViaSkin Peanut, a treatment delivered via a skin patch aimed at reducing peanut allergy in children aged […]

November 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The Future is (Syn)Bio: How and when do we get there?

Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout

Welsh Scientists Use CRISPR to Engineer Cancer-Killing T cells

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

Streamlining Vaccine R&D with Labflow Automation

Infographic: What is RNAi Therapy? Targeting the Untargetable

Can this French Biotech Make it Easier to Rescue People from Hypoglycemia?

German Biotech Reels in €34M for its Cancer-Killing Technology

French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A

Welcome to Amsterdam, EMA! Your New Home Post-Brexit

British and German Scientists Chuck Proteins in the Trash to Uncover their Function

After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!